8-K
filed May 10, 2024, 7:59 PM ET
ticker EWTX
CIK 0001710072
other material
confidence high
sentiment neutral
materiality 0.70
Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners
Edgewise Therapeutics, Inc.
- New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.
- Prior $125M ATM program with BofA Securities terminated on May 10, 2024.
- Leerink will receive up to 3% commission on gross proceeds from shares sold.
- Company has no obligation to sell shares and may suspend or terminate the program at any time.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Edgewise Therapeutics, Inc. terminated Common Stock Sales Agreement with BofA Securities, Inc. (effective 2024-05-10).
- Action
- termination
- Agreement
- atm program
- Counterparty
- BofA Securities, Inc.
- Effective
- 2024-05-10
Exact text from the filing
In connection with the Company's entry into the Sales Agreement, on May 10, 2024, the Company delivered written notice to BofA Securities to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Edgewise Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $175,000,000 (effective 2024-05-10).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Leerink Partners LLC
- Value
- up to $175,000,000
- Effective
- 2024-05-10
Exact text from the filing
On May 10, 2024, Edgewise Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") under which the Company may offer and sell shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having aggregate sales proceeds of up to $175,000,000 (the "Shares"), from time to time, through an "at the market offering" program under which Leerink will act as sales agent.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.